Our targeted therapies 
are being evaluated for
the treatment of multiple 
cancer indications.
 
Our Clinical Trials

Deciphera Pharmaceuticals is committed to advancing improved treatments for patients with cancer. Our pipeline of tumor-targeted therapies and immuno-targeted therapies are being evaluated for the treatment of multiple cancer indications including:

GIST:

Gastrointestinal stromal tumors (GIST) are tumors in the gastrointestinal tract, most commonly in the stomach or small intestine. GIST tumors are predominantly driven by KIT kinase mutations. Approximately 6,700 – 19,000 patients in the U.S., Europe and Japan are diagnosed with GIST tumors annually[1].

Systemic Mastocytosis:

Systemic mastocytosis is a disorder where mast cells (immune cells) are abnormally increased in multiple organs including the bone marrow. Mastocytosis has been associated with a primary mutation in KIT exon 17. Approximately 6,700[2] patients in the U.S., Europe and Japan are diagnosed with systemic mastocytosis annually.

Additional resources:
American Cancer Society

Our Clinical Trials:

.
DCC-2618

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

DCC-3014
Study of DCC-3014 in Patients With Advanced Malignancies

[1] Estimated based on incidence rate extrapolated to population of selected major markets.

[2] Estimated based on incidence rate extrapolated to population of selected major markets, see: Br J Haematol. 2014 Aug;166(4):521-8. doi: 10.1111/bjh.12916. Epub 2014 Apr 25.

Back to Top